Cipla Ltd. — Capital/Financing Update 2020

Feb 7, 2020

==> picture [104 x 91] intentionally omitted <==

==> picture [76 x 76] intentionally omitted <==

==> picture [95 x 33] intentionally omitted <==

Cipla Expands Women’s Health Portfolio through Acquisition of 4 Key Brands from Wanbury

Mumbai, India; February 07, 2020: Cipla Ltd. (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the acquisition of nutrition products’ portfolio from Wanbury Ltd. Cipla has acquired 4 brands — CPink, CDense, Productiv and Folinine to further strengthen its presence in women’s health.

The nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies. This includes supplements such as multivitamins, multimineral and antioxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health.

Nikhil Chopra, Head India Business, Cipla Limited, said: "We are focused on strengthening our play in the women’s health segment by amplifying our four-decade long presence in this category. Through this newly acquired portfolio, we shall be catering to a wide range of patient needs including nutritional deficiencies, bone health and sexual health”.

As per (IQVIA MAT Dec’19), the above molecules previously commercialized by Wanbury Ltd have a market size of INR 3,100 Cr in India with sales value of INR 59.6 Cr.

About Cipla :

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec’19), 3rd largest in the pharma private market in South Africa (IQVIA MAT Dec’19), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and

==> picture [95 x 33] intentionally omitted <==

deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit Cipla, or click on Twitter, Facebook, LinkedIn.

Corporate Communications Investor Relations Heena Kanal Naveen Bansal

E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com